DGX Company Profile and Key Details

Q: Who are the executives of DGX?

Mr. Shawn C. BevecVice President of Investor RelationsMr. Gary D. SamuelsSenior Vice President & Chief Communications OfficerMr. Sam A. SamadExecutive Vice President & Chief Financial OfficerMr. Stephen H. RusckowskiExecutive ChairmanMs. Kristin Lee Wallace Esq.Senior Vice President & Chief Compliance OfficerMs. Cecilia K. McKenneySenior Vice President & Chief HR OfficerMr. Michael E. PrevoznikSenior Vice President & Gen. CounselMr. Michael J. DeppeSenior Vice President, Corporation Controller & Chief Accounting OfficerMs. Catherine T. DohertySenior Vice President of Regional Bus.esMr. Patrick T. PlewmanSenior Vice President of Diagnostic ServicesMr. James E. DavisChairman, Chief Executive Officer & PresMs. Gabrielle WolfsonSenior Vice President and Chief Information & Digital Officer

NYSE : DGX

Quest Diagnostics

$192.30

3.07+1.62%

At Close 4:00 PM

64.35

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Quest Diagnostics Incorporated (DGX) stock surged +1.62%, trading at $192.30 on NYSE, up from the previous close of $189.23. The stock opened at $190.00, fluctuating between $188.65 and $193.43 in the recent session.

Stock Snapshot

189.23

Prev. Close

21.5B

Market Cap

188.645

Day Low

22.57

P/E Ratio

8.52

EPS (TTM)

8.53

Cash Flow per Share

190

Open

111.82M

Number of Shares

193.43

Day High

99.48%

Free Float in %

57.95

Book Value

1.38M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	190.00	193.46	188.65	192.30	1.64M
Feb 04, 2026	185.34	189.80	185.13	189.23	1.3M
Feb 03, 2026	184.78	189.13	184.69	185.17	802.79K
Feb 02, 2026	186.01	186.93	182.36	185.00	1M
Jan 30, 2026	183.82	187.19	183.82	187.03	1.14M
Jan 29, 2026	182.17	183.97	181.82	182.35	453.7K
Jan 28, 2026	183.02	183.58	181.63	182.74	838.06K
Jan 27, 2026	181.51	184.39	181.48	184.24	667.84K
Jan 26, 2026	182.14	183.79	181.37	182.53	680.93K
Jan 23, 2026	181.94	182.44	179.73	181.02	848.68K
Jan 22, 2026	185.11	185.47	182.01	182.16	1.75M
Jan 21, 2026	189.02	189.75	184.43	184.65	1.14M
Jan 20, 2026	187.69	191.07	186.83	188.95	1.48M
Jan 16, 2026	189.40	190.96	188.75	189.49	1.13M
Jan 15, 2026	187.15	190.99	186.43	190.26	1.25M
Jan 14, 2026	180.50	187.10	179.83	186.77	1.24M
Jan 13, 2026	176.86	180.42	175.47	179.96	1.07M
Jan 12, 2026	175.81	176.06	173.51	175.94	694.92K
Jan 09, 2026	177.52	178.30	174.43	174.44	942.35K
Jan 08, 2026	178.19	180.66	176.70	177.74	870K

Contact Details

Secaucus, NJ 07094

United States

https://www.questdiagnostics.com 973 520 2700

About Company

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Stock Peers

MTD

-6.88-0.50%

Mettler-Toledo International Inc.$1,382.85 TMO

-22.86-4.04%

Thermo Fisher Scientific Inc.$542.36 WAT

-7.44-1.94%

Waters Corporation$376.89 DHR

-3.78-1.72%

Danaher Corporation$215.75 CRL

-17.92-8.89%

Charles River Laboratories International, Inc.$183.70 IQV

-21.58-10.65%

IQVIA Holdings Inc.$180.96 A

-3.34-2.51%

Agilent Technologies, Inc.$129.64 RVTY

-4.31-4.15%

Revvity, Inc.$99.52 QGEN

-0.48-0.93%

Qiagen N.V.$51.23 ENZ

-0.0678-17.77%

Enzo Biochem, Inc.$0.31

Company Overview

Quest Diagnostics Incorporated (NYSE:DGX) closed at $192.30 USD, gaining $3.07 (1.62%) from the previous close of $189.23. The stock is currently within 5% of its 52-week high $157.20 and $197.55. With a market capitalization of about $21.50 billion, Quest Diagnostics Incorporated is classified as a large-cap and shows lower-than-market volatility (beta ~0.68). Key stats such as the average daily volume over the past year has been around 1.03 million shares, in line with its 52-week average. Headquartered in Secaucus, NJ, Quest Diagnostics Incorporated operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO James E. Davis, the company employs approximately 55,000 people and listed since December 17, 1996. Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally.

Technical Performance

DGX has shown mixed momentum, gaining 7.39% over the past week and -0.3% over the past quarter, though year-to-date performance is up 8.89%. Short-term trend indicators are bearishly aligned (SMA20 4.45%, SMA50 5.75%, SMA200 7.27%). The stock’s 14-day RSI is 65.16 (firm momentum), while the ATR of 3.76 points to moderate volatility. The stock remains sitting in the mid-range of its 52-week band, trading -2.66% below its high and over 22.33% above its low. Average 10-day trading volume of 979.73 thousand shares is in line with the 3-month average of 998.11 thousand, indicating normal recent market interest.

Valuation Metrics

Quest Diagnostics Incorporated trades at a P/E ratio of 22.17, slightly below the S&P 500 average, with a price-to-sales ratio of 1.98 and a price-to-book ratio of 2.96 suggesting the stock is closer to book value. The P/FCF stands at 15.4, also above market averages.

Dividend & Fair Value

Quest Diagnostics Incorporated last paid a dividend of 3.2 per share, this equals a trailing yield of roughly 1.96%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $229.94. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Quest Diagnostics Incorporated generated EPS of $8.52 over the past year. Five-year average earnings growth is 4.04%. Wall Street analysts project EPS growth of 8.0% annually over the next five years. The latest quarter delivered EPS of $2.17. The next quarter is forecast at $2.36. Next year's EPS is expected at $4.02. Analyst sentiment is neutral. Analyst rating data shows there are 4 Strong Buy ratings, 2 Buy ratings, 12 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $215.00 to $175.00. The high target offers 11.8% upside. The low target suggests -9.0% downside. The mean target is $193.56. This offers 0.66% upside. Quest Diagnostics Incorporated earnings surprise history is a mixed track record. The quarter that ended October 21, 2025, missed forecasts by -13.55%. The prior quarter beat by 1.95%. Over the last six quarters, Apple has recorded several small beats. These include -11.69% in July 23, 2024.

Shareholding & Insider Activity

Quest Diagnostics Incorporated has 111.82 million shares outstanding. The public float is 111.24 million shares, elevated short interest at 4.11% of float. This equals 4.03 million shares. The short ratio is 3.2 days. Institutional investors hold 99.55% of the float. Insiders own 0.4%. RUSCKOWSKI STEPHEN H holds 334.83 thousand shares, Davis J. E. has 120.48 thousand shares and GUINAN MARK has 73.58 thousand shares. Over the past six months, insider transactions show net selling. They sold 52.51 thousand shares across 10 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Quest Diagnostics generated $9.87B in revenue, or $87.36 per share. Gross margin was 32.86%, operating margin 13.63%, and net profit margin 8.82%. Returns are healthy, with ROA at 6.21% and ROE at 13.81%.
On valuation metrics, Quest Diagnostics trades at a P/E of 22.17, P/S of 1.98 and P/B of 2.96. The current ratio is 1.13 and quick ratio is 1.04. Operationally, the company’s inventory turnover is 38.91 and cash conversion cycle is -15.12 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.88, supported by a cash flow-to-debt ratio of 0.30.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2024, Quest Diagnostics posted revenue of $9.87B, down slightly from $9.25B in the prior quarter. Gross profit was $3.24B (margin 32.86%). Operating income was $1.35B (margin 13.6%). Net income was$871.00M (EPS $7.85).
The company ended the quarter with $686.00M in cash and short-term investments, a total debt of $5.37B, and net debt of $4.68B. Total assets were $14.02B, with equity of $6.42B. Financials further reflected stability, with operating cash flow of $1.27B, free cash flow of $864.00M, and capital expenditures of - $408.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that Quest Diagnostics Incorporated stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.44%, with price expected at $193.15 by February 19, 2026, within a range of $189.09 to $197.49 3-Month Outlook: Projected rise of 11.51%, reaching $214.44 by May 05, 2026, with a range of $210.37 to $218.67. 1-Year Outlook: Projected gain of 8.52%, with price at $208.69 by February 05, 2027, within a range of $205.05 to $212.96.

Key Takeaways

Quest Diagnostics Incorporated (NYSE:DGX) shares are flat 8.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Quest Diagnostics Incorporated trading at a premium to the broader market with a P/E of 22.17. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $158.82, suggesting -17.41% downside. Our AI forecast model points to short-term strength (0.44% over two weeks), a medium-term rise (11.51% over three months), and a longer-term gain (8.52% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Quest Diagnostics Incorporated (DGX) stock price?

Quest Diagnostics Incorporated (NYSE: DGX) stock price is $192.30 in the last trading session. During the trading session, DGX stock reached the peak price of $193.43 while $188.65 was the lowest point it dropped to. The percentage change in DGX stock occurred in the recent session was 1.62% while the dollar amount for the price change in DGX stock was $3.07.

DGX's industry and sector of operation?

The NYSE listed DGX is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. Quest Diagnostics Incorporated designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of DGX?

Mr. Shawn C. Bevec
Vice President of Investor Relations
Mr. Gary D. Samuels
Senior Vice President & Chief Communications Officer
Mr. Sam A. Samad
Executive Vice President & Chief Financial Officer
Mr. Stephen H. Rusckowski
Executive Chairman
Ms. Kristin Lee Wallace Esq.
Senior Vice President & Chief Compliance Officer
Ms. Cecilia K. McKenney
Senior Vice President & Chief HR Officer
Mr. Michael E. Prevoznik
Senior Vice President & Gen. Counsel
Mr. Michael J. Deppe
Senior Vice President, Corporation Controller & Chief Accounting Officer
Ms. Catherine T. Doherty
Senior Vice President of Regional Bus.es
Mr. Patrick T. Plewman
Senior Vice President of Diagnostic Services
Mr. James E. Davis
Chairman, Chief Executive Officer & Pres
Ms. Gabrielle Wolfson
Senior Vice President and Chief Information & Digital Officer

How DGX did perform over past 52-week?

DGX's closing price is 22.33% higher than its 52-week low of $157.20 where as its distance from 52-week high of $197.55 is -2.66%.

How many employees does DGX have?

Number of DGX employees currently stands at 55,000.

Link for DGX official website?

Official Website of DGX is: https://www.questdiagnostics.com

How do I contact DGX?

DGX could be contacted at phone 973 520 2700 and can also be accessed through its website. DGX operates from 500 Plaza Drive, Secaucus, NJ 07094, United States.

How many shares of DGX are traded daily?

DGX stock volume for the day was 1.38M shares. The average number of DGX shares traded daily for last 3 months was 1.03M.

What is the market cap of DGX currently?

The market value of DGX currently stands at $21.50B with its latest stock price at $192.30 and 111.82M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	55000
Beta	0.64
Sales or Revenue	$9.87B
5Y Sales Change%	0.492%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

DGX Company Profile and Key Details

Quest Diagnostics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Key Takeaways

Price Forecast & Outlook

Valuation Metrics